Roche Aims to Build Affordable, Tolerable Obesity Drug Portfolio: Genentech CEO
Written By : sheeba farhat
Published On 2026-03-17 12:30 GMT | Update On 2026-03-17 12:30 GMT
New York: Roche's Ashley Magargee, chief executive of its Genentech unit, said on Monday the company is striving to build a portfolio of obesity medicines that are both tolerable in terms of side effects and affordable.
"A lot of patients are dropping off therapy for various reasons," said Magargee, speaking at the Reuters Pharma USA 2026 event in Philadelphia, pointing to long-term weight maintenance and combination therapies for people who are not responding to just one medicine as two areas of focus.
"How can you not just get these new medicines to patients, but also, how can you get an affordable portfolio of medicines to treat all the needs across the patient population now?" she said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.